Clinical Scorecard: Transcranial Pulse Stimulation of the Prefrontal Cortex in Patients with Major Depressive Disorder: Results from a Randomized Clinical Trial
At a Glance
Category
Detail
Condition
Major Depressive Disorder (MDD)
Key Mechanisms
Transcranial pulse stimulation (TPS) modulates brain activity through shock waves that enhance neurogenesis and angiogenesis.
Target Population
Adults aged 18 to 65 years with MDD, confirmed by diagnosis.
Care Setting
Clinical trial setting at Hong Kong Polytechnic University.
Key Highlights
TPS is a noninvasive brain stimulation technique showing promise for MDD treatment.
The study utilized a double-blind, sham-controlled design with 12 sessions of TPS.
Primary outcome measured was the change in MADRS score post-intervention.
Participants included treatment-naive individuals or those on stable medication.
Adverse events were monitored throughout the treatment sessions.
Guideline-Based Recommendations
Diagnosis
MDD diagnosis confirmed by psychiatrist or Mini International Neuropsychiatric Interview.
Management
TPS treatment consisted of 3 sessions per week for 4 weeks targeting the left DLPFC.
Monitoring & Follow-up
Adverse events assessed using a predefined checklist after each session.
Risks
Exclusion criteria included severe psychiatric comorbidities and contraindications for noninvasive brain stimulation.
Patient & Prescribing Data
Adults aged 18 to 65 years with a baseline HAMD-17 score of 14 or higher.
TPS was delivered with specific energy flux densities and pulse frequencies to the left DLPFC.
Clinical Best Practices
Ensure blinding integrity by assessing participants' group-allocation guesses.
Utilize MR-based navigation for precise targeting of TPS.
by Penny Ping Qin, Minxia Jin, Rebecca Laidi Kan, Ivan Chak, Bella Bingbing Zhang, Wanda Chau, Ami Li, Tim Tianze Lin, Adam Weili Xia, Sharie Xiao Wang, Tifei Yuan, Teris Cheung, Roland Beisteiner, Lei Sun, Frank Padberg, Georg S. Kranz
